# Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

> **NCT04881240** · PHASE1 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia, Refractory
- Pediatric ALL

## Interventions

- **BIOLOGICAL:** CD19-CAR(Mem) T-cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna
- **DEVICE:** CliniMACS
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT04881240
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-14
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04881240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04881240, "Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04881240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*